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Renal cell carcinoma (RCC) affects approxi-
mately 60,000 people in Europe and in the 
United States each year (Ferlay et al., 2007; 
Jemal et al., 2010), and is associated with 
high rates of morbidity and mortality. The 
incidence of RCC is rising, perhaps because 
of the widespread use of abdominal imaging, 
resulting in an increased detection of small 
renal masses, and surgical intervention for 
these (Hollingsworth et al., 2006; Falebita et 
al., 2009). Surgery remains an integral part 
of the management of RCC, and is the only 
curative treatment in patients with disease 
confined to the kidney and its regional vas-
culature and lymph nodes. However, about 
30% of patients are diagnosed with meta-
static renal cell carcinoma (mRCC) at pres-
entation (Motzer et al., 1996) and a similar 
proportion will later develop metastases 
(Leibovich et al., 2003). Until 2007, a combi-
nation of cytoreductive nephrectomy (CN) 
and immunotherapy, usually interferon-α, 
was considered to be the standard of care 
for those patients presenting with mRCC 
deemed fit enough, although cytokine 
therapy was associated with modest ben-
efits and much toxicity (Coppin et al., 2005). 
The basis for nephrectomy in the context 
of metastatic disease was provided by two 
similar prospective trials which randomized 
patients to CN plus interferon or inter-
feron alone. Combined analysis of the two 
trials demonstrated a median survival of 
13.6 months for surgery plus interferon, and 
7.8 months for interferon alone (HR = 0.69, 
95% CI = 0.55–0.87, p = 0.002; Flanigan et 
al., 2004). The simplest rationale for why 
CN might improve survival in mRCC is a 
reduction in overall tumor burden, thus 
delaying time to a lethal burden of disease; 
other theories include a decrease in the 
amount of tumor shedding and systemic 
signaling from the primary renal mass, 
effective palliation of pain, bleeding and 
paraneoplastic syndromes, and removal 
of a source of significant immunosuppres-
sion. The latter was proposed on the basis 
of reports of   spontaneous regression in 
mRCC, which occurs very rarely, but this 
phenomenon was also observed in series 
when surgery was not performed (Russo 
and O’Brien, 2008). Despite the evidence for 
a combined modality approach to mRCC 
in the cytokine era, these agents did not 
improve clinical outcomes when studied 
in the adjuvant setting (Pizzocaro et al., 
2001; Messing et al., 2003; Atzpodien et al., 
2005), and were not tested as neoadjuvant 
treatment due to their side effects and the 
very limited response rates observed in the 
primary tumors.
Since that time, a number of new, bio-
logical therapies for mRCC have emerged, 
resulting in marked improvements in clinical 
outcomes in this disease. The multi-targeted 
tyroskine kinase inhibitors (TKIs), which 
include sunitinib, sorafenib, and pazopanib, 
have all demonstrated significant gains in 
median progression-free survival times 
in phase III trials, and probably improve 
overall survival as well (Escudier  et al., 
2007a; Motzer et al., 2007; Sternberg et al., 
2010a,b). Temsirolimus and everolimus are 
mammalian target of rapamycin (mTOR) 
inhibitors and were also established as effec-
tive therapies for patients with poor-prog-
nosis, untreated mRCC and for second line 
therapy after TKIs respectively (Hudes et al., 
2007; Motzer et al., 2008b). Bevacizumab, 
a humanized monoclonal antibody against 
vascular endothelial growth factor (VEGF) 
improved progression-free survival when 
combined with interferon, compared to 
interferon alone in two phase III trials 
(Escudier et al., 2007b; Rini et al., 2008). 
The lack of overall survival benefit reported 
in many of these trials could be explained 
by the fact that the majority of subjects 
received subsequent anti-angiogenic treat-
ments. However, it is well recognized that, 
despite these advances, treatment for most 
patients remains non-curative, and that 
these therapies have serious limitations. 
A lack of systematic tissue collection in 
the phase III trials of these agents means 
there is inadequate   understanding of the 
 biological mechanisms underlying response 
and resistance to treatment, and there are 
no established predictive biomarkers, and 
no basis for selection of therapy for an 
individual patient. Successful treatment of 
mRCC is based on knowledge of critical 
molecular signaling pathways, but clinico-
pathological models such as the MSKCC 
scoring system, developed to categorize 
patients treated with cytokines into favora-
ble, intermediate and poor risk prognosis 
groups (Motzer et al., 2002), are still applied 
to patients treated in the kinase inhibi-
tor era. Although newer tools have been 
developed for use in patients treated with 
anti-angiogenic therapies (Motzer et al., 
2008a; Heng et al., 2009), these are largely 
based on traditional markers of risk, rather 
than molecular characteristics and so there 
remains scope for refinement.
One approach therefore is to look toward 
pre-operative studies to inform us of the 
optimal treatment of RCC, whether it is early 
or advanced stage. Pre-operative treatment 
is a broad term which is often interchanged 
with, and includes, neoadjuvant treatment; 
the latter specifically applies to patients 
treated with curative intent, but in who 
there is locally advanced, and often inop-
erable tumor, at the outset. Neoadjuvant 
therapy is increasingly used in many tumor 
types for the following reasons: it can down-
size a bulky tumor thus enabling safer and 
more effective surgery, there is early treat-
ment of micrometastatic disease, it pro-
vides an in vivo test of systemic treatment 
response, and importantly, it provides tissue 
which is critical for research into surrogate 
markers of biological processes. A neoadju-
vant approach may be particularly relevant 
to RCC, in which the primary tumors tend 
to grow slowly, reducing the risk of signifi-
cant disease progression while surgery is 
awaited, and because clinical experience of 
the newly available systemic therapies indi-
cates that tumor shrinkage occurs early after 
treatment initiation and is often followed 
by a prolonged period of disease stability. 
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the potential for disease progression on pre-
operative therapy which then excludes the 
patient from nephrectomy. Of course, this 
is also one of the arguments in favor of pre-
operative therapy, in that it might prevent 
poor-prognosis patients who are refractory 
to medical therapies from undergoing mor-
bid surgery.
Data from phase III trials integrating 
pre-operative therapy and surgery, like 
the EORTC SURTIME and French-led 
CARMENA studies, will hopefully estab-
lish whether a pre-operative approach is an 
effective means of oncologic control in RCC. 
Nonetheless, these early pre-operative trials 
are instructive. Firstly, it seems clear that 
our current method of assessing response 
to treatment is inadequate in the anti-
angiogenic therapy era. If the vast major-
ity of patients in the phase II pre-operative 
trials achieve minor reductions in disease 
volume, yet have heterogenous clinical out-
comes, then standard CT imaging and the 
RECIST system is not able to distinguish 
those patients in whom the natural disease 
course is altered by this treatment. Newer 
radiology modalities which assess tumor 
blood flow, such as arterial spin labeling 
magnetic resonance imaging (MRI) and 
dynamic contrast-enhanced MRI (DCE-
MRI), may be more suitable, but require 
validation (de Bazelaire et al., 2008; Hahn 
et al., 2008). Secondly, but perhaps more 
importantly, trial design in pre-operative 
studies provides an opportunity for much-
needed tissue collection, so far omitted 
from large clinical trial protocols in RCC. 
Biopsies of the primary and metastatic sites 
at important time points such as at baseline, 
disease response and disease progression 
are the key to understanding the molecu-
lar mechanisms underlying sensitivity and 
resistance to the newer treatments. Multiple 
tissue specimens are required, because it is 
becoming clear that substantial intra- and 
inter-tumoral genetic heterogeneity exists 
in RCC (Moch et al., 1998; Dalgliesh et al., 
2010). Intratumoral heterogeneity may 
contribute significantly to drug resistance 
(Gerlinger and Swanton, 2010; Lee et al., 
2011), and may present a challenge to bio-
marker discovery in RCC.
On this basis, the European Union 
multi-disciplinary Personalized RNA 
Interference to Enhance the Delivery of 
Individualized Cytotoxic and Targeted 
therapeutics (PREDICT) consortium is 
a formal partial response as per RECIST, 
but tumor enhancement as assessed by con-
trast CT decreased in a significant number 
of patients (75%), and this seemed to cor-
relate with histologic necrosis. There did not 
appear to be any increase in surgical mor-
bidity attributable to sunitinib, and with a 
short median follow up of 6.5 months, this 
study assesses pre-operative therapy from a 
surgical safety, rather than disease control, 
perspective. Powles et al. (2011) recently 
reported on two prospective phase II stud-
ies of pre-operative sunitinib in 52 patients 
with mRCC. Overall, the RECIST clinical 
benefit and nephrectomy rates were high 
(73 and 71% respectively), despite a partial 
response rate of only 6%, and a median 
reduction in longest tumor diameter of 
12%. Reassuringly, no patients became 
inoperable while on systemic therapy. This 
led the authors to conclude that sunitinib 
prior to nephrectomy was an effective way 
of controlling disease, but also to question 
whether the endpoint of response rate in 
this, and other trials, is appropriate.
Similar results were seen in a pre-oper-
ative study of sorafenib, although these 
patients were considered to be suitable 
surgical candidates up-front (Cowey  et 
al., 2010). Thirty patients (17 with locally 
advanced, and 13 with metastatic disease) 
were treated with sorafenib for a median of 
33 days prior to nephrectomy. Most patients 
achieved shrinkage of the primary tumor, 
although the median degree of reduction 
was −9.6%, and therefore, most patients had 
stable disease by RECIST (93%). A subset of 
patients also underwent contrast-enhanced 
CT assessment and amongst the 17 evalu-
able patients, 15 had a reduction in intra-
tumoral density. Despite a short interval 
between cessation of sorafenib and surgery 
(median of three days), no additional surgi-
cal morbidity was observed in this study.
Finally, a phase II feasibility study of pre-
surgical bevacizumab in 50 patients with 
mRCC suitable for CN found a median pro-
gression-free survival time of 11 months, 
comparable to the results of the up-front 
sunitinib and temsirolimus trials (Hudes 
et al., 2007; Motzer et al., 2007; Jonasch 
et al., 2009). However, concerns were raised 
about the rates of delayed wound healing 
related to anti-angiogenic therapy – dem-
onstrated in nine patients at four post-
operative weeks, and one patient required 
re-operation for wound dehiscence – and 
Furthermore, rates of objective response in 
the primary tumor appear to be higher with 
drugs such as sunitinib than was observed 
with cytokine therapy (Shuch et al., 2008; 
van der Veldt et al., 2008). Pre-operative, 
rather than neoadjuvant, therapy includes 
patients with metastatic disease, and as well 
as defining the role of surgery in patients 
treated with biological therapies, it may 
provide answers to the many unmet clini-
cal needs in mRCC described above.
Pre-operative studies in RCC are limited 
to a small number of retrospective analyses 
and phase II studies. Retrospective surgi-
cal series, each involving small numbers 
of patients, mainly focused on the safety 
aspects of peri-operative therapy with 
anti-angiogenic drug therapy. Thomas 
et al. (2009b) presented two retrospec-
tive reviews; the first of these included 19 
patients treated with sunitinib, sorafenib 
or bevacizumab with interleukin-2 prior 
to surgical resection, for locally advanced, 
locally recurrent or metastatic RCC, and 
reported low morbidity in most patients, 
consistent with the results from other insti-
tutions (Amin et al., 2008; Margulis et al., 
2008; Shuch et al., 2008; Chapin et al., 2011). 
The second paper from the Cleveland Clinic 
group not only suggested that pre-operative 
sunitinib was safe, but also hinted that this 
approach could be used to convert non-
operable into operable tumors (Thomas 
et al., 2009a). Nineteen patients who were 
deemed unsuitable for nephrectomy on 
the basis of locally advanced or metastatic 
disease were treated with sunitinib; partial 
responses were observed in 16%, and stable 
disease in another 37%, and four patients 
had sufficient tumor regression (either 
in the primary or metastatic disease) to 
facilitate nephrectomy (21%). The largest 
retrospective review of pre-surgical sys-
temic therapy was published recently and 
indicates that early, minor response in the 
primary tumor (median size of reduction 
−36.4%) predicts for improved overall sur-
vival (Abel et al., 2011).
A prospective, phase II trial of pre-
operative sunitinib in patients with locally 
advanced or metastatic RCC enrolled 20 
patients, all of who were deemed suitable 
for nephrectomy (Hellenthal et al., 2010). 
Seventeen of the 20 patients had some 
reduction in tumor diameter on CT at 
2 months with a mean change in tumor 
diameter of −11.8%. Only one patient had www.frontiersin.org  December 2011  | Volume 1  |  Article 51  |  3
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currently recruiting patients for several pre-
operative biopsy studies in mRCC (Swanton 
et al., 2010). The PREDICT trial designs 
incorporate functional imaging studies and 
comprehensive analysis of primary and sec-
ondary disease sites, using novel methods of 
personalized tumor-derived small hairpin 
RNA and high-throughput small interfer-
ing RNA screens, with the following aims: 
identification of predictive and surrogate 
biomarkers, determination of the mecha-
nisms of resistance and response to VEGF-
targeted therapy, and identification of new 
targets in RCC. It is our opinion that ration-
ally designed pre-operative RCC studies 
provide a unique opportunity to study drug 
treatments for this disease in vivo, and that 
this may impact on future clinical practice 
in RCC. This approach almost guarantees 
the acquisition of tissue; however, careful 
and standardized measures of quality con-
trol are necessary to ensure that the tissue 
collected is suitable for genomic and other 
analyses.
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